Needham & Company raised its price target on Buy-rated ISIS Pharmaceuticals (NASDAQ: ISIS) from $29 to $36 saying more positive ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE